DEC 08 2006

RM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 1 of 1

| ATTORNEY DOCKET NO. | SERIAL NO. | | | | |
|---------------------|------------|--|--|--|--|
| 6794-000141/US/01 | 09/869,333 | | | | |
| APPLICANT | | | | | |
| Franco Pamparana | | | | | |
| FILING DATE | GROUP | | | | |
| July 26, 2001 | 1614 | | | | |

| U.S. P | ATENT DO | CUMENTS | | | | | | |
|------------------|------------------------|--------------------|------|---------|--------------------|---------------------------------|--|--|
| Ref. / Desig. | Examiner's Initials | Document Number | Date | Name | Class/ Subclass | (If appropriate) Filing Date | | |
| FORE | IGN PATEN | IT DOCUMENTS | | | | | | |
| Ref. Desig. | Examiner's Initials | Document Number | Date | Country | Class/ Subclass | Translation Yes No | | |
| | | | | , | | | | |

| UINE | K DOCUME | NTS (including Author, Title, Date, Pertinent Pages, etc.) |
|----------------|------------------------|--|
| Ref. Desig. | Examiner's Initials | |
| 1. | 1 | GISSI-Prevenzione Investigators, Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial, The Lancet (1999) Vol. 354, 447-455 |
| 2. | | Christine M. Albert, M.D., et al., Blood Levels of Long-Chain n-3 Fatty Acids and the Risk of Sudden Death, N. Engl J. Med, (2002) Vol. 346, No. 15, 1113-1118 |
| 3. | | Maggie B. Covington, M.D., Omega-3 Fatty Acids, American Family Physician (2004), Vol. 74, No. 1, 133-140 |
| 4. | | Chenchen Wang MD et al., Effects of Omega-3 Fatty Acids on Cardiovascular Disease, AHRQ Publication No. 04-E009-2 (2004) Evidence Report/Technology Assessment No. 94 |
| 5. | | TRICOR® 48 mg and 145 mg, (fenofibrate tablets), Abbott Laboratories (2004) pp. 1-8 |
| 6. | | The Field Study Investigators, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial, www.thelancet.com (2005), pp. 1-13 |
| 7. | | The Allhat Officers ad Coordinators of the Allhat Collaborative Research Group, Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs. Chlorthalidone, JAMA (2000) Vol. 283, No. 15, 1967-75 |
| 8. | h | CARDURA® (doxazosin mesylate) Tablets, Pfizer Inc. (2002) pp. 1-19 |
| 9. | 1 | Thalitone®, Monarch Pharmaceuticals® (2004) |

| | | | _ | | | | | | - |
|-----------|-----|------|---------------|----|------------------|---|-----------|------|---|
| Examiner: | the | | \mathcal{L} | 12 | Date Considered: | 3 | <u>/2</u> | 07 | _ |
| | | | | | | | | | |

EXAMINER: Please Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EV 63901755 US